Literature DB >> 2371601

Prostate carcinoma: an autopsy evaluation of the influence of age, tumor grade, and therapy on tumor biology.

R R Gatling1.   

Abstract

This report represents a review of 1,641 routine autopsies. Prostate carcinoma was identified in 172 cases (10% of all autopsies) and was the direct or contributing cause of death in 29 (2%). Frequency of prostate carcinoma increased with increasing age, but the mortality rate was inversely related to age as indicated by 30% mortality in those younger than 60 years old, 24% of those between 60 and 70 years old, and 7.5% of those older than 70 years. Of those with carcinoma, 83% died of other, unrelated causes; of those who died, 80% had poorly differentiated (grade 3 or 4) tumors. Given the indolent biologic nature of well differentiated tumors in those older than 70 years, prostate carcinoma should not in most instances be regarded as life-threatening with or without treatment in older individuals. The tumor seems to be biologically more aggressive in younger men, especially those younger than 60 years.

Entities:  

Mesh:

Year:  1990        PMID: 2371601     DOI: 10.1097/00007611-199007000-00016

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  3 in total

Review 1.  Temporal trends and racial disparities in global prostate cancer prevalence.

Authors:  Timothy R Rebbeck; Gabriel P Haas
Journal:  Can J Urol       Date:  2014-10       Impact factor: 1.344

2.  The Relationship Between PSA and Total Testosterone Levels in Men With Prostate Cancer.

Authors:  Jose M Flores; Helen L Bernie; Eduardo Miranda; Bruno Nascimento; Elizabeth Schofield; Nicole Benfante; Sigrid Carlsson; John P Mulhall
Journal:  J Sex Med       Date:  2022-02-05       Impact factor: 3.937

Review 3.  Management of complications of androgen deprivation therapy in the older man.

Authors:  Supriya G Mohile; Karen Mustian; Kathryn Bylow; William Hall; William Dale
Journal:  Crit Rev Oncol Hematol       Date:  2008-10-25       Impact factor: 6.312

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.